View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
February 28, 2019

Top therapy areas in biosimilar trials

By GlobalData Healthcare

Over the past decade, the number of clinical trials using a biosimilar treatment has been on the rise. GlobalData extracted all biosimilar drug trials up to December 21, 2018 and then broke them down by therapy area.

The largest number of biosimilar clinical trials took place in oncology, followed by immunology, hematological disorders, metabolic disorders, and musculoskeletal.

When split into phases GlobalData found biosimilar trials were most numerous in Phase I and Phase III across the major therapy areas (Figure 1). Musculoskeletal had the largest number of Phase I trials and a much higher number of Phase IV trials than any other therapy area. One of the largest treatment areas for approved biologic drugs is arthritis, so this may explain why there are so many post-marketing trials in this therapy area.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy